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Discussion
Dr Davis C. Drinkwater (Nashville, Tenn). I have a couple of
questions.
If I could set the basis for doing this study, have you, in your
clinical series, had issues with clotted PTFE grafts or early failure
with your grafts? Do you use aspirin or warfarin early on in your
clinical practice, and did you do so with these piglets? I guess most
people would use aspirin, if not warfarin, at least early in the
postoperative course.
What was the size mismatch relative to the adult human? For
example, we have tried to put in at least a 22-mm graft as an
extracardiac conduit. Was this a size mismatch that might have
created flow-and-eddy problems that could potentially create early
stenosis issues? I am wondering about the size mismatch being a
cause. Setting that aside, potentially where will you harvest from
the human if the organs that are taken are the liver and the heart?
What portion of the cava is available, the renal, the suprarenal?
Dr Wells. Thank you for the questions.
We have not really observed a problem with thrombosis. We
were concerned about the reports coming from Italy that there
might be up to a 30% to 40% cross-sectional luminal reduction in
the serially magnetic resonance imaging–studied vena caval ex-
tensions for Fontan completion. Therefore that in and of itself was
the impetus to determine whether there is something better. Also,
we have been concerned in our practice about leaving patients
without aggressive anticoagulation for the first at least 6 months
after putting in the PTFE graft. Therefore, you are going to subject
a child to at least 6 months of anticoagulation, which you might be
able to avoid. And I should add that in these studies there was no
anticoagulation. Thanks for pointing that out.
As far as the size of the homografts, we tried to use clinically
appropriate sizes. Therefore, these were 18- to 20-mm homografts,
3 cm to 4 cm in length, and we think that the typical patient in
whom we are doing this for Fontan completion gets a conduit of 18
to 20 mm and about 5 cm in length. Therefore we believed that this
was clinically appropriate.
Finally, either the innominate vein in a larger donor or poten-
tially the inferior vena cava, which will have more branches, could
be sites. The infrarenal cava could be a site for harvesting, and we
are just getting interested in investigating the best place from
which to take that venous tissue.
Dr Vaughn A. Starnes (Los Angeles, Calif). You are implying,
then, that this would be homograft tissue and not xenograft tissue?
Dr Wells. There is evidence currently that there is no differ-
ence between homograft and xenograft for the depopulated tissues.
That is animal work that is fairly convincing. However, I think if
you want to use this clinically during our foreseeable lifetime, we
probably need allografts. We probably need human tissue to get
this going.
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